Sampling Strategies for Tissue Microarrays to Evaluate Biomarkers in Ovarian Cancer

被引:11
|
作者
Permuth-Wey, Jenny
Boulware, David
Valkov, Nikola
Livingston, Sandra
Nicosia, Santo
Lee, Ji-Hyun
Sutphen, Rebecca
Schildkraut, Joellen [2 ]
Narod, Steven [3 ]
Parker, Alex [4 ]
Coppola, Domenico
Sellers, Thomas
Pal, Tuya [1 ]
机构
[1] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Canc Epidemiol & Genet, MRC CANCONT, Tampa, FL 33612 USA
[2] Duke Univ, Durham, NC USA
[3] Womens Coll Hosp, Ctr Res Womens Hlth, Toronto, ON M5S 1B2, Canada
[4] Mayo Clin, Coll Med, Jacksonville, FL 32224 USA
关键词
NONPOLYPOSIS COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; MISMATCH-REPAIR; TUMOR HETEROGENEITY; BREAST-CANCER; RISK; IMMUNOHISTOCHEMISTRY; VALIDATION; CARCINOMA; HMLH1;
D O I
10.1158/1055-9965.EPI-08-0713
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Tissue microarrays (TMA) enable rapid analysis of biomarkers in large-scale studies involving archival tumor specimens, however, their utility in heterogeneous tumors such as ovarian cancer is limited. Methods: In this study, immunohistochemical analysis was done on TMAs comprised of epithelial ovarian cancer (EOC) to estimate the prevalence of loss of expression of three mismatch repair proteins. TMAs were initially created using cores sampled from the center of donor tissue blocks from 59 EOC cases. Full sections were subsequently created and levels of expression were compared between tissues sampled from the central portion versus the periphery. Followup analyses were done by obtaining cores from the periphery of up to five additional donor blocks per case. A linear mixed model for each protein was used to investigate differences between results from the initial and follow-up blocks. Results: In the original TMAs created using centrally sampled cores, loss of mismatch repair expression was noted in 17 (29%) of the 59 cases. By comparison, analyses from peripherally sampled cores revealed loss of expression in only 6 of these 17 cases. For each protein, significant differences (P < 0.05) were detected between results from the initial donor block and the majority of the follow-up blocks. Conclusions: Our investigations, based on EOC, suggest that sampling variability in protein expression may result when TMAs are used. Thus, at least for EOC, it is important to preferentially sample from the periphery of tumor blocks where exposure to tissue fixatives is optimal. (Cancer Epidemiol Biomarkers Prev 2009;18(1):28-34)
引用
收藏
页码:28 / 34
页数:7
相关论文
共 50 条
  • [31] Candidate genes for testicular cancer evaluated by in situ protein expression analyses on tissue microarrays
    Skotheim, RI
    Abeler, VM
    Nesland, JM
    Fosså, SD
    Holm, R
    Wagner, U
    Florenes, VA
    Aass, N
    Kallioniemi, OP
    Lothe, RA
    NEOPLASIA, 2003, 5 (05): : 397 - 404
  • [32] Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections
    Abir A. Muftah
    Mohammed A. Aleskandarany
    Methaq M. Al-kaabi
    Sultan N. Sonbul
    Maria Diez-Rodriguez
    Chris C. Nolan
    Carlos Caldas
    Ian O. Ellis
    Emad A. Rakha
    Andrew R. Green
    Breast Cancer Research and Treatment, 2017, 164 : 341 - 348
  • [33] Characterization of new serum biomarkers in breast cancer using lipid microarrays
    Yonekubo, Yoshiya
    Wu, Ping
    Esechie, Aimalohi
    Zhang, Yueqiang
    Du, Guangwei
    TUMOR BIOLOGY, 2010, 31 (03) : 181 - 187
  • [34] Molecular Complexity of Colorectal Cancer: Pathways, Biomarkers, and Therapeutic Strategies
    Yang, Zhengdong
    Wang, Xinyang
    Zhou, Huiying
    Jiang, Minghan
    Wang, Jinghui
    Sui, Bowen
    CANCER MANAGEMENT AND RESEARCH, 2024, 16 : 1389 - 1403
  • [35] An Evaluation of Focal Adhesion Kinase in Breast Cancer by Tissue Microarrays
    Sheen-Chen, Shyr-Ming
    Huang, Chun-Ying
    Chan, Yi-Chia
    Tsai, Ching-Hua
    Chi, Shun-Yu
    Wu, Shih-Chung
    Huang, Chao-Cheng
    Tang, Rei-Ping
    Eng, Hock-Liew
    Ko, Sheung-Fat
    Lee, Yi-Wei
    Liang, Jiun-Lung
    Huang, Eng-Yen
    Chen, Hui-Chun
    Rau, Kung-Ming
    ANTICANCER RESEARCH, 2013, 33 (03) : 1169 - 1173
  • [36] Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis
    Abbott, Karen L.
    Lim, Jae-Min
    Wells, Lance
    Benigno, Benedict B.
    McDonald, John F.
    Pierce, Michael
    PROTEOMICS, 2010, 10 (03) : 470 - 481
  • [37] A Perspective on Ovarian Cancer Biomarkers: Past, Present and Yet-To-Come
    Ueland, Frederick R.
    DIAGNOSTICS, 2017, 7 (01):
  • [38] Progress in The Study of Glycosylation of Ovarian Cancer Biomarkers
    Xue Tian
    Li Yan-Hong
    Li Zheng
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2017, 44 (10) : 865 - 876
  • [39] Autoantibody biomarkers for the detection of serous ovarian cancer
    Katchman, Benjamin A.
    Chowell, Diego
    Wallstrom, Garrick
    Vitonis, Allison F.
    LaBaer, Joshua
    Cramer, Daniel W.
    Anderson, Karen S.
    GYNECOLOGIC ONCOLOGY, 2017, 146 (01) : 129 - 136
  • [40] Searching for a system: The quest for ovarian cancer biomarkers
    Rodland, Karin D.
    Maihle, Nita J.
    CANCER BIOMARKERS, 2010, 8 (4-5) : 223 - 230